Last updated: 5 April 2024 at 5:25pm EST

Keith T. Flaherty Net Worth



Keith Flaherty KNTE stock SEC Form 4 insiders trading

Keith has made over 8 trades of the Kinnate Biopharma stock since 2016, according to the Form 4 filled with the SEC. Most recently Keith exercised 50,000 units of KNTE stock worth $59,000 on 7 June 2018.

The largest trade Keith's ever made was exercising 50,000 units of Kinnate Biopharma stock on 7 June 2018 worth over $59,000. On average, Keith trades about 3,991 units every 23 days since 2013. As of 7 June 2018 Keith still owns at least 59,732 units of Kinnate Biopharma stock.

You can see the complete history of Keith Flaherty stock trades at the bottom of the page.



What's Keith Flaherty's mailing address?

Keith's mailing address filed with the SEC is 800 WEST EL CAMINO REAL, SUITE 180, MOUNTAIN VIEW, CA, 94040.

Insiders trading at Kinnate Biopharma

Over the last 4 years, insiders at Kinnate Biopharma have traded over $0 worth of Kinnate Biopharma stock and bought 12,223,600 units worth $79,803,534 . The most active insiders traders include Carl L Gordon, Advisors Llc Orbi Med Capit... e Helen Sabzevari. On average, Kinnate Biopharma executives and independent directors trade stock every 74 days with the average trade being worth of $2,699,377. The most recent stock trade was executed by James B. Tananbaum on 8 May 2023, trading 1,780,000 units of KNTE stock currently worth $4,984,000.



What does Kinnate Biopharma do?

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.



Kinnate Biopharma executives and stock owners

Kinnate Biopharma executives and other stock owners filed with the SEC include: